David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on LinkedIn:
“Bringing the latest insights to the GULF! A pivotal discussion on making FLAURA2 the new 1L standard for our EGFRm advanced NSCLC patients.
A significant step beyond osimertinib monotherapy.”
You can also read: FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Overall Survival Across Prognostic Subgroups in EGFR-Mutated Advanced NSCLC — Presented at ESMO 2025
